Literature DB >> 31197826

A systematic review and meta-analysis of prognostic factors for remission in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma.

Sarah Guillon1, Nathalie Popescu1, Juliette Phelippeau1, Martin Koskas1.   

Abstract

BACKGROUND: Endometrial cancer and atypical hyperplasia are rare in young women but create a dilemma between desire for pregnancy and oncologic outcomes.
OBJECTIVE: To identify remission rates and associated prognostic factors in patients undergoing fertility-sparing management for endometrial cancer and atypical hyperplasia. SEARCH STRATEGY: MEDLINE was searched for studies published between January 1, 1950 and July 31, 2017 using various search terms. SELECTION CRITERIA: Studies evaluating fertility-sparing management in patients aged between 19 and 44 years with atypical hyperplasia or stage I endometrial cancer. DATA COLLECTION AND ANALYSIS: Use of PRISMA guidelines to conduct a meta-analysis of the proportion of patients in remission and meta-regression analysis to test the effect of possible prognostic factors for remission. MAIN
RESULTS: A total of 3673 studies were screened; 65 studies including 1604 patients met the inclusion criteria. The remission rate was 0.75 (95% CI, 0.73-0.77). Operative hysteroscopy for endometrial sampling was associated with higher remission rates (OR 2.31; 95% CI, 1.10-4.84; P=0.03). Studies with higher ratios of infertile women were associated with higher remission rates (OR 4.21; 95% CI, 1.44-12.33; P<0.01).
CONCLUSION: Operative hysteroscopy is the preferred endometrial sampling method for patients with atypical hyperplasia or endometrial cancer undergoing fertility-sparing management.
© 2019 International Federation of Gynecology and Obstetrics.

Entities:  

Keywords:  Adenocarcinoma; Atypical hyperplasia; Endometrial cancer; Fertility sparing; Meta-analysis; Operative hysteroscopy; Remission; Systematic review

Mesh:

Year:  2019        PMID: 31197826     DOI: 10.1002/ijgo.12882

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  11 in total

Review 1.  Fertility after Cancer: Risks and Successes.

Authors:  Chiara Di Tucci; Giulia Galati; Giulia Mattei; Alessandra Chinè; Alice Fracassi; Ludovico Muzii
Journal:  Cancers (Basel)       Date:  2022-05-19       Impact factor: 6.575

2.  Cancer of the corpus uteri: 2021 update.

Authors:  Martin Koskas; Frédéric Amant; Mansoor Raza Mirza; Carien L Creutzberg
Journal:  Int J Gynaecol Obstet       Date:  2021-10       Impact factor: 4.447

3.  Insulin Resistance and Metabolic Syndrome Increase the Risk of Relapse For Fertility Preserving Treatment in Atypical Endometrial Hyperplasia and Early Endometrial Cancer Patients.

Authors:  Xingchen Li; Yuan Fan; Jiaqi Wang; Rong Zhou; Li Tian; Yiqin Wang; Jianliu Wang
Journal:  Front Oncol       Date:  2021-11-30       Impact factor: 6.244

4.  Management of Recurrent Endometrial Cancer or Atypical Endometrial Hyperplasia Patients After Primary Fertility-Sparing Therapy.

Authors:  Junyu Chen; Dongyan Cao; Jiaxin Yang; Mei Yu; Huimei Zhou; Ninghai Cheng; Jinhui Wang; Ying Zhang; Peng Peng; Keng Shen
Journal:  Front Oncol       Date:  2021-09-09       Impact factor: 6.244

Review 5.  Progesterone Actions and Resistance in Gynecological Disorders.

Authors:  James A MacLean; Kanako Hayashi
Journal:  Cells       Date:  2022-02-13       Impact factor: 6.600

6.  Chances of pregnancy and live birth among women undergoing conservative management of early-stage endometrial cancer: a systematic review and meta-analysis.

Authors:  Erica Herrera Cappelletti; Jonas Humann; Rafael Torrejón; Pietro Gambadauro
Journal:  Hum Reprod Update       Date:  2022-02-28       Impact factor: 15.610

7.  Fertility-Sparing Treatment for Endometrial Cancer or Atypical Endometrial Hyperplasia Patients With Obesity.

Authors:  Junyu Chen; Dongyan Cao; Jiaxin Yang; Mei Yu; Huimei Zhou; Ninghai Cheng; Jinhui Wang; Ying Zhang; Peng Peng; Keng Shen
Journal:  Front Oncol       Date:  2022-02-18       Impact factor: 6.244

Review 8.  Fertility-Sparing Approaches in Atypical Endometrial Hyperplasia and Endometrial Cancer Patients: Current Evidence and Future Directions.

Authors:  Nayanar-Adela Contreras; Jordi Sabadell; Paula Verdaguer; Carla Julià; Maria-Eulalia Fernández-Montolí
Journal:  Int J Mol Sci       Date:  2022-02-25       Impact factor: 5.923

9.  Metabolic syndrome is an independent risk factor for time to complete remission of fertility-sparing treatment in atypical endometrial hyperplasia and early endometrial carcinoma patients.

Authors:  Yingqiao Ding; Yuan Fan; Xingchen Li; Yiqin Wang; Jianliu Wang; Li Tian
Journal:  Reprod Biol Endocrinol       Date:  2022-09-05       Impact factor: 4.982

Review 10.  Hysteroscopy in the management of endometrial hyperplasia and cancer in reproductive aged women: new developments and current perspectives.

Authors:  Salvatore Giovanni Vitale; Gaetano Riemma; Jose Carugno; Benito Chiofalo; George Angelos Vilos; Stefano Cianci; Mehmet Sukru Budak; Bernardo Portugal Lasmar; Antonio Raffone; Ilker Kahramanoglu
Journal:  Transl Cancer Res       Date:  2020-12       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.